

# Index

- A**
- Acetylated LDL (AcLDL), 35, 37
  - Adherens junctions
    - blood–brain barrier, 397, 441
    - lung endothelium, 264
    - lymphatic endothelial cells, 211, 213, 217, 228
    - Notch signaling, 188, 334
    - VEGF effects on, 187–188, 193, 195
  - Adhesion molecules, 480
  - Adrenomedullin (ADM), 220
  - Aging, 573. *See also* Vascular aging
  - AGM (aorta-gonad-mesonephros) region, 1, 3, 6–8
  - Alagille syndrome, 327–328
  - ALK1* (activin-like receptor kinase 1), 65–67
  - Alzheimer’s disease, 387, 404
  - Anchoring filaments of lymphatic vessels, 209–210
  - Angioblasts, origins and migration of, 97
  - Angiogenesis
    - intussusceptive, 134, 299, 522–523, 527
    - key signaling factors, 186–189
    - overview, 99
    - remodeling, 99
    - targeting via resolution of inflammation, 495–508
  - Angiopoietin-1, 135–136, 496
  - Angiopoietin-2, 219, 496
  - Antiangiogenic therapies (AATs), 186, 191–192, 194
  - Aortic arches, 106–107
  - Argonaute 2 (Ago2), 286, 289–290
  - Arterial regression, 106–107
  - Arterial specification, Notch signaling, 332
  - Arterial-venous specification, 16–19
  - Arteriovenous differentiation, and Notch signaling, 244, 249
  - Arteriovenous malformations (AVMs), 64–67
    - brain, 402
    - described, 64–67, 108–109
    - genetic causes, 110–111
    - heterogeneity, 110–111
    - mechanosensitivity, 109–110
    - Notch signaling, 249
    - organ vascularization, 108–115
    - pulmonary, 110–115
    - surgical shunting of cardiopulmonary blood flow, 112–115
  - Astrocytes, 397
  - Atherosclerosis
    - hemorrhage in atherosclerotic plaque, 195
    - positive feedback loop of stiffness, 285
    - pro-resolving mediators, 503
    - role of lymphatics in, 553–555
    - shear stress, effects of, 290–291
    - S1P signaling, 266–267
- B**
- Basement membrane
    - disease suppression by healthy, 86–88
    - lymphatic vessels, 209, 211
  - Basement membrane assembly
    - endothelial cell interactions with mural cells, 78–88
    - genetic knockout studies, 81–85
    - integrin control of, 86
    - pericyte recruitment, 79, 81–83
  - Blood–brain barrier (BBB)
    - cell types, 395, 397
    - dysregulation in pathological conditions, 402–405
    - molecular signatures, 397–398
    - in neurodegenerative disease, 404–405
    - regulation of, 395–406
    - signaling pathways, 398–402
    - S1P, 265–266
    - therapeutics, 405–406
    - vascular dysfunction, 574
    - Wnt signaling, 424–426, 432
  - Blood–brain barrier (BBB) models
    - adhesion assay, 447
    - commercially available BMECs, 444–445
    - diapedesis, 447–448
    - general considerations for, 443–444
    - human stem cell–derived, 445–446
    - immortalized human cerebral microvascular endothelial cells, 445
    - investigating immune cell extravasation across, 447
    - investigating immune cell extravasation across under physiological flow, 448–452
    - overview, 441–443
    - primary human brain endothelial cells, 444
    - transendothelial electrical resistance (TEER), 444–446
  - Blood vessel maturation, 100
  - Blood vessel patterning
    - arteriovenous malformations (AVMs), 64–67
    - beauty and complexity of, 51–67
    - CNS, 57–59

## Index

- Blood vessel patterning (*Continued*)
  - concepts in, 52–54
  - coronary, 61–63
  - examples of organ-specific vascular patterning, 57
  - future advances in understanding, 67
  - kidney, 63–65
  - mechanical cues, 56–57
  - modes, 53
  - overview, 52–57
  - signaling pathways, 54–56
  - skin, 59–61
  - soluble/tethered vascular patterning signals, 54–56
- Blood vessels
  - development, 298–299
  - fibrosis, 285
  - S1P signaling, 263–264
  - vascular aging, 573–586
- BML-111, 505–506
- BMP signaling
  - blood vessel patterning, 52, 55
  - endothelial cell differentiation, 3
  - hereditary hemorrhagic telangiectasia (HHT), 65–67
- Bone repair and regeneration, role of angiogenesis in, 189–190
- Brain
  - endothelium, and S1P signaling, 265–266
  - microvasculature and microbiota–host interactions, 597–598
  - Wnt signaling, 424–426, 432
- Brain microvascular endothelial cells (BMECs), 441–452
- Brain tumor angiogenesis, 402
- Branchial arches, 106–107
- Bronchopulmonary dysplasia (BPD), 38
- Button junctions
  - adrenomedullin, S1P, and CD36, effects of, 220
  - altered protein expression, 217
  - angiopoietin-2 and VEGF family members, effects of, 219
  - cell entry between, 214–215
  - Delta-like4/Notch, effects of, 219–220
  - developmental changes, 214, 216–217
  - formation in lacteals, 229
  - in initial lymphatics (capillaries), 212–214, 361–362
  - mechanistic manipulations, effects of, 218
  - overview, 205–206
  - permeability, 228–229
  - plasticity, 214, 216–220
  - role of, 362
  - sprouting lymphangiogenesis, 217
  - YAP/TAZ signaling, effect of, 220
- C
- CADASIL, 335–336
- Calcification, in vascular aging, 582
- Calcium dynamics, lymphatic intracellular, 366–368
- Cancer
  - angiogenesis as treatment target, 505
  - connexins role in, 126–128
  - Notch signaling and tumor progression, 250–251
  - platelets and tumor angiogenesis, 140–141
  - progression promotion by macrophages, 498
  - T cell–endothelial cell interactions, 464–465
  - tumor-associated lymphangiogenesis, prostanoid regulation of, 159–160
- Capillaries, disease suppression by healthy, 86–88
- Capillary tube assembly, growth factors controlling, 89–90
- Cardiovascular disease
  - atherosclerosis, 195, 266–267, 285, 290–291, 503, 553–555
  - coronary microcirculatory dysfunction, 194–195
  - endothelial colony-forming cells (ECFCs) in ischemic, 39
  - heart failure, 556–559
  - hypertension, 550–551
  - lymphatic vessels in, 549–558
  - myocardial infarction, 128, 284–285, 555–556
  - obesity, 551–553
  - overview, 549–550, 557
  - vascular aging, 573–574
- Cardiovascular phenotypes in genetic knockout of basement membrane components, 81–85
- Cardiovascular system, and mechanical homeostasis, 283–284
- CCL21–CCR7 signaling axis, 479
- CD36
  - button junctions, effects on, 220
  - lipid metabolism, role in, 537–539
- Cell-cycle arrest, in hemogenic endothelial cell specification (HECS), 7
- Cell fate. *See* Endothelial cell fate determination
- Central conducting lymphatic anomaly (CCLA), 313
- Cerebral cavernous malformations (CCMs), 345–355, 402–403
- Cerebral ischemic stroke (CIS), 194–195
- Cerebral microbleed, 195
- Chemokine signaling, and blood vessel patterning, 56
- Chronic myeloid leukemia (CML), 38–39
- Chronic obstructive pulmonary disease (COPD), 40
- Chylothorax, 227, 232, 234–235, 314
- Circuitry, vascular, 105–106
- Circulation, 105–106
- c-kit, 7
- CLAPO syndrome, 313
- cloche*, 4
- CLOVES syndrome, 313
- CNS, and vascular patterning, 57–59
- Connexins (Cxs)
  - lymphatic, 365–366
  - organization into gap junction channels, 122

- overview, 121–123
- role during developmental angiogenesis, 125–126
- role during pathological angiogenesis, 126–128
- role in vascular functions, 123–125
- structure, 121–122
- Connexons, 122, 365
- Coronary microcirculatory dysfunction, 194–195
- Coronary vascular patterning, 61–63
- Corrosion casting, 519, 522–523
- COUPTFII, 17–21
- COVID-19
  - clinical observations, 520
  - endothelial injury and endothelialitis, 523–525
  - microanatomy and molecular profiling, 527–529
  - microvascular injury, 522–523
  - overview, 519
  - perivascular immune response, 525–527
  - platelets, role of, 142
  - pulmonary, anatomy of, 520–522
- CXCL12-CXCR4 signaling, in blood vessel patterning, 56, 61, 63–64
- Cyclooxygenase 1 (COX-1), 150
- Cyclooxygenase 2 (COX-2), 150, 152–156, 158–161
  
- D**
- Delta-like4, 219–220
- Dendritic cells (DCs)
  - in lymph, 472–473
  - migration of, 473–474, 477–484
  - molecules involved in migration, 478–482
- Diabetes mellitus, 233, 249
- Diabetic retinopathy, 423–424, 503–504, 508
- Diapedesis, 442, 444, 447–450, 452
- Dicer1, 289–290, 292
- Disease suppression by healthy capillaries and basement membranes, 86–88
  
- E**
- Electrophysiology, lymphatic muscle, 363–365
- Embryoid bodies, 170–171
- Endocytic adaptors, 297–304
- Endocytosis, of VEGF receptors, 300–304
- Endometriosis, prostanoid effect on, 153
- Endothelial cell differentiation
  - factors guiding, 3–6
  - hemogenic endothelial cell specification, 6–8
  - overview, 2–3
- Endothelial cell fate determination
  - arterial-venous, 16–19
  - lymphatic, 19–23
  - lymphatic specification, 20–21
  - lymphatic valve cell fate, 22–23
  - Notch signaling, 13–23, 332–333
  - sprouting lymphangiogenesis, 21–22
  - tip cell/stalk cell determination and shuffling, 14–16
- Endothelial cells
  - lipid metabolism, 535–544
  - mural cell communication, 327–338
  - Notch signaling, 244–246
  - organ-specificity, 580–581
  - pericyte interactions in cerebral cavernous malformations, 345–355
  - T-cell interactions, 459–465
  - Wnt/frizzled signaling pathway, 415–432
- Endothelial colony-forming cells (ECFCs)
  - in clinical disorders, 38–40
  - definition, 27–30
  - isolation and culture from blood, 30, 34–36
  - origin of circulating human, 32–34
  - phenotypic and functional characterization, 36–37
  - therapeutic potential, 40–42
  - vasculogenic ability of, 37–38
- Endothelialitis, 523–525
- Endothelial junctions, in lymphatics, 205–221
- Endothelial progenitor cells (EPCs)
  - controversies, 30–32
  - putative, 31–32
- Endothelial-to-hematopoietic transition, in hemogenic endothelial cell specification (HECS), 6
- ENG, 65–67
- EP<sub>3</sub>, 149, 151–152, 154–155, 158–161
- EP<sub>4</sub>, 151–152, 154, 157–158, 160–161
- Epsins, 297–304
- ETV2, and endothelial cell differentiation, 3–4
- Exosomes, 191–194
- Extracellular matrix (ECM)
  - endothelial cell differentiation, 6
  - endothelial cell–ECM interactions in morphogenesis, 76–78
  - endothelial cell–mural cell interactions in basement membrane deposition, 78–88
  - growth factor coordination in morphogenesis and maturation, 88–91
  - overview, 75–76
  - stiffness, 284–290, 316
  - tissue mechanics, 284, 289
  - vascular aging, 579–580
- Extracellular vesicles, 191–194
- Eyes
  - diabetic retinopathy, 423–424, 503–504, 508
  - microvasculature and microbiota–host interactions, 597–598
  - Wnt signaling and eye vasculature, 421–422
  
- F**
- Fatty acid–binding proteins (FABPs), 536, 538, 541
- Fatty acids
  - metabolism in angiogenesis, 541
  - oxidation and angiogenesis, 542–544

## Index

- Fatty acids (*Continued*)  
  synthesis and angiogenesis, 542  
  uptake and transport, 536–538  
Fatty acid transport proteins (FATPs), 536, 538–539  
Fibroblast growth factor (FGF), in endothelial cell differentiation, 5–6  
Fibrosis  
  COVID-19, 528  
  idiopathic pulmonary fibrosis (IPF), 40, 285, 288–291  
  inflammation and homeostasis–fibrosis balance, 285–286  
  microcirculatory dysfunction, 196  
  and microRNAs (miRNAs), 286–292  
  perivascular, 579  
  post-myocardial infarction, 284–285  
Fik1, in endothelial cell differentiation, 5  
Fli1a/b, in endothelial cell differentiation, 4–5  
Fluid shear stress regulation. *See* Shear stress  
Foxf1, in endothelial cell differentiation, 3  
  
**G**  
Gap junctions  
  connexins, 121–128  
  lymphatic muscle, 365  
  lymphatic valve development, 365–366  
Generalized lymphatic anomaly (GLA), 312  
Gene regulation, GPCR signaling, 261–263  
Gene therapy, and endothelial colony-forming cells (ECFCs), 41  
Glycocalyx  
  changes during aging, 579–580  
  exosome uptake and release, 192–193  
  vascular endothelium–tumor cell interactions, 192  
Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1), 536–539  
Gorham–Stout disease (GSD), 312–313  
G-protein-coupled receptors (GPCRs), 261–263  
GPR124/RECK/WNT7 signaling, and blood–brain barrier, 400–401  
Growth factors. *See also specific growth factors*  
  capillary tube assembly and maturation, 89–91  
  ECM coordination in vascular morphogenesis, 88–91  
Guidance tunnels, vascular, 77–79, 90  
Gut microbiota, 591–598  
Gut microvasculature, and microbiota–host interactions, 592–595  
  
**H**  
Healing. *See also* Wound healing  
  inflammation, effect of, 285  
  and mechanical homeostasis, 284  
Heart. *See also* Cardiovascular disease  
  mechanical homeostasis, 283–284  
  surgical shunting of cardiopulmonary blood flow, 112–115  
Heart failure, 556–559  
Heart fibrosis, 284–286  
Heart vascularization, 103–104  
Hedgehog signaling, 3  
Hematopoiesis  
  definitive, 6  
  primitive, 6  
Hemodynamics  
  of blood flow, 108–109  
  influence on morphogenesis, 99–100  
Hemogenic endothelial cell specification (HECS)  
  factors guiding, 6–8  
  overview, 6  
Hemorrhage in atherosclerotic plaque, 195  
Hepatic factor, 114–115  
Hereditary hemorrhagic telangiectasia (HHT), 65–67, 111, 126  
Homeostasis. *See also* Mechanical homeostasis  
  fluid shear stress regulation, 287  
  inflammation and homeostasis–fibrosis balance, 285–286  
Hutchinson–Gilford progeria syndrome (HGPS), 583–585  
Hydrogels, 175–176  
Hydrostatic pressure, and lymph flow, 206–207, 228  
Hyperinflammatory diseases, SPMs as markers in, 502  
Hypertension, 550–551  
Hypoxia  
  link between angiogenesis and inflammation, 496–497  
  tumor angiogenesis stimulated by, 497–498  
Hypoxia-inducible factors (HIFs), 5, 496–497  
  
**I**  
Idiopathic pulmonary fibrosis (IPF), 40, 285, 288–291  
Immune cell trafficking, mechanisms in, 441–453  
Immune response, to COVID-19, 525–527  
Inflammation  
  angiogenesis as interdependent, 496–497  
  homeostasis–fibrosis balance, 285–286  
  lymphatic permeability disruption, 234–235  
  lymphatic pumping, impact on, 371  
  macrophages, role of, 498–499  
  Notch signaling, 264  
  prostanoid regulation of lymphangiogenesis, 155–158  
  shear stress promotion of, 291  
  skin, 386  
  S1P signaling, 264  
  targeting angiogenesis via resolution of, 495–508  
  T cell–endothelial cell interactions, 459–465

- unresolved in disease, 499–502
- vascular aging, 576, 578
- Inflammation-associated lymphangiogenesis (IAL), 549–550, 556
- Inflammatory bowel disease, 386, 503
- Initial lymphatics, button and zipper junctions in, 205–221
- Integrins
  - control of vascular basement membrane assembly, 86
  - extracellular matrix–stimulated vascular morphogenesis, 76–78
- Intercellular junctions
  - button and zipper junctions in initial lymphatics, 205–221
  - evolution of understanding of lymphatic, 206–210
  - between lymphatic endothelial cells, 211–212
  - lymphatic vascular permeability, 228–229
- Interorgan vascularization, 105–108
- Intussusception of vessels, 98–99
- Intussusceptive angiogenesis, 134, 299, 522–523, 527
- In utero colonization hypothesis, 591
- Ischemia-reperfusion injuries, 128
  
- K**
- Kaposiform lymphangiomatosis (KLA), 312
- Kidney
  - vascular heterogeneity in nephron, 101
  - vascularization, 102–103
  - vascular patterning, 63–65
- Klippel–Trenaunay syndrome (KTS), 313
  
- L**
- Leukocyte migration
  - adhesion molecules, 480
  - CCL21–CCR7 signaling axis, 479
  - lymph node entry and egress, 480, 482–486
  - methods for studying, 473–478
  - molecules involved, 478–482
  - S1P signaling, 479–480
  - stepwise through afferent lymphatic vessels, 474, 478
- Lipid droplets (LDs), 535, 537–539, 544
- Lipid metabolism, endothelial
  - fatty acid metabolism in angiogenesis, 541
  - fatty acid oxidation and angiogenesis, 542–544
  - fatty acid synthesis and angiogenesis, 542
  - fatty acid uptake and transport, 536–538
  - link to systemic metabolism, 541
  - mechanism of uptake by endothelial cells, 536
  - overview, 535–536
  - regulation of uptake and transport, 539–541
  - triglyceride-rich lipoprotein uptake and transport, 538–539
- Lipopolysaccharide (LPS), 595–597
- Lipoprotein lipase (LpL), 536–539
- Lipoxins, 495, 499–502, 505–508
- Liver
  - fibrosis, 196, 284, 286
  - microvasculature and microbiota–host interactions, 595–597
- Lungs
  - COVID-19, 519–529
  - idiopathic pulmonary fibrosis (IPF), 40, 285, 288–291
  - mechanical homeostasis, 284
  - microcirculatory dysfunction, 194
  - S1P signaling, 264–265
  - vascularization, 104–105
- LXA<sub>4</sub> (lipoxin A<sub>4</sub>), 502, 504–508
- Lymph, cellular composition of, 472–473
- Lymphangiogenesis
  - 3D assays in vitro, 171
  - definition, 299
  - hydrogel scaffolds, 175–176
  - platelets, 133–143
  - prostanoid regulation in inflammation, 155–158
  - prostanoid regulation in lymphedema, 155–158
  - prostanoid regulation of tumor-associated, 159–160
  - sprouting, 21–22, 217
  - S1P signaling, 264
- Lymphangion, 362, 365, 368, 381–382
- Lymphatic anomalies
  - classification of primary, 311–314
  - genes mutated in, 234–235, 313
  - lymphatic vascular development, 315–320
  - molecular mechanisms driving, 309–321
- Lymphatic capillary networks, 358–359
- Lymphatic contractions, 380–383
- Lymphatic dysfunction, in obesity, 552–553
- Lymphatic endothelial cells (LECs)
  - lymphatic tissue engineering, 168–176, 179
  - organization of lymphatic vasculature, 471–472
  - progenitors, 299
  - specification, 315
- Lymphatic filariasis, 385–386
- Lymphatic function
  - in neurological disease, 387–388
  - in normal tissues, 379–383
  - in pathologies, 383–388
- Lymphatic malformations. *See* Lymphatic anomalies
- Lymphatic muscle
  - electrophysiology, 363–365
  - gap junctions and contraction coordination, 365
- Lymphatic muscle cell (LMC), 311, 317, 380–383, 386–387
- Lymphatic organ engineering and regeneration, 174–178
- Lymphatic pumping
  - lymphatic clearance and pump function, 359–372
  - mechanics of, 379–388
  - nitric oxide modulation of, 383

## Index

- Lymphatic system
    - anatomy and organization, 379–380
    - in cardiovascular physiology, 549–558
    - migration of leukocytes, 469–487
    - overview, 167–168, 469
    - S1P signaling, 266
  - Lymphatic tissue engineering
    - biomaterial scaffolds, 175–176
    - 2D in vitro, 168–170
    - 3D in vitro, 170–172
    - microfluid devices, 172–174
    - for regeneration in vivo, 174–178
    - schematic drawing of strategies, 169
  - Lymphatic transport
    - lymphatic muscle gap junctions
      - and contraction coordination, 365
    - myogenic responses to transmural pressure changes, 368, 370
    - shear stress, responses to, 370
    - signaling to contractile proteins, 368
  - Lymphatic valves
    - cell fate, 22–23
    - development and gap junctions, 365–366
    - development signaling pathways, 235
    - evolution of understanding of, 206–210
    - formation, 317
    - lymphatic pumping, role in, 380–382
    - primary and secondary, concept of, 211
  - Lymphatic vascular cell fate, 19–23
  - Lymphatic vascular development
    - signaling pathways, 317–320
    - stepwise process, 315–317
  - Lymphatic vascular permeability
    - cell–cell junctions, 228–229
    - measurement methods, 230
    - overview, 227–228
    - pathways for solutes, 231–232
  - Lymphatic vascular permeability disruption
    - inflammation, 234–235
    - lymphatic malformations, 234–235
    - lymphedema, 233–234
    - metabolic disease, 232–233
  - Lymphatic vasculature
    - organization of, 470–472
    - structure and functioning, 310–311
  - Lymphatic vasculature development
    - Notch signaling, 20–21
    - overview, 19–20
  - Lymphatic vessels
    - anchoring filaments, 209–210
    - basement membrane, 209, 211
    - in cardiovascular diseases, 549–558
    - cellular migration through, 472–473
    - development, 299
    - endothelial junctions, 205–221
    - evolution of understanding
      - of junctions and valves, 206–210
    - leukocyte trafficking in, 469–487
    - overview, 359–362
    - permeability, 227–236
    - structure in vivo, 174–175
  - Lymphedema
    - cancer-related, 383, 385
    - congenital, 314
    - lymphatic permeability disruption, 233–234
    - and obesity, 565–570
    - pathologies associated with, 383–385
    - primary, 314
    - prostanoid regulation of lymphangiogenesis, 155–158
    - secondary, 310, 565
    - syndromic, 314
    - with visceral involvement, 314
  - Lymphedema praecox, 314
  - Lymphedema tarda, 314
  - Lymph formation, 380
  - Lymph nodes
    - DC and T-cell entry into, 480, 482–484, 486
    - lymphatic vasculature organization, 471–472
    - lymphocyte egress from, 484–486
  - Lymph sac formation, 315–316
  - Lymph transport
    - chemical signal impact on pumping, 370–371
    - collecting lymphatic contraction patterns, 362–363
    - intracellular calcium dynamics, 366–368
    - lymphatic muscle electrophysiology, 363–365
    - overview, 359–362
    - pressure–volume relationship, 362–363
  - Lymph vessels-on-a-chip systems, 172–174
  - Lysine-specific histone demethylase 1A (LSD1), 4
  - LYVE1, 360–361
- ## M
- Macrophages
    - inflammation, 498–499
    - in wound healing, 504–505
  - Massive localized lymphedema (MLL), 566, 568, 570
  - Mechanical homeostasis
    - failure of, 284–285, 288
    - fluid shear stress regulation, 287
    - microRNAs (miRNAs), 286–292
    - overview, 283–284
    - tissue architecture, reversible and nonreversible changes in, 286
  - Mechanosensitivity
    - arteriovenous malformations (AVMs), 109–110
    - pulsatile versus continuous flow, 113–114
  - Metabolic disease, lymphatic permeability disruption in, 232
  - Metastasis
    - prostanoid regulation of lymphatic, 159–160

- tumor cell adhesion and transmigration, 192–193
  - Methicillin-resistant *Staphylococcus aureus* (MRSA), 386–387
  - Microbiota–host interactions
    - brain and eye microvasculature, 597–598
    - gut microvasculature, 592–595
    - liver microvasculature, 595–597
    - overview, 591–592
  - Microcirculatory dysfunction
    - cerebral ischemic stroke (CIS), 194–195
    - cerebral microbleed, 195
    - coronary, 194–195
    - hemorrhage in atherosclerotic plaque, 195
    - hepatic fibrosis, 196
    - overview, 185–186
    - pulmonary fibrosis, 196
  - Microfluid devices, 172–174, 449–453
  - MicroRNAs (miRNAs)
    - in disease, 286–292
    - fluid shear stress regulation, 287, 290–292
    - hemogenic endothelial cell specification (HECS), 8
    - in mechanical homeostasis, 286–292
    - overview, 286
    - regulation of fluid shear stress, 287–288
    - tissue stiff and abnormal regulation of, 288–290
  - Microvascular injury, in COVID-19, 522–523
  - Microvascular permeability
    - key signaling factors, 186–189
    - in tumors, 192
    - VEGF, role of, 192
  - Microvasculature, and gut microbiota, 591–598
  - Migration of endothelial cells, and Notch signaling, 245
  - Mitochondria, dysfunctional, 576, 578
  - Modeling
    - brain vasculature immune interactions in vitro, 441–453
    - vascular aging in vitro, 581–586
  - Molecular profiling of COVID-19, 528–529
  - Mononuclear cells (MNCs), 30, 32–36
  - Multiple sclerosis, and blood–brain barrier dysregulation, 405
  - Mural cells
    - Notch signaling, 334–336
    - recruitment during sprouting angiogenesis, 16
    - recruitment in blood vessel maturation, 98, 100
    - vascular basement membrane assembly, 78–88
    - vascular endothelial cell communication, 327–338
  - Mycobacterium tuberculosis*, 387
  - Myeloid angiogenic cells (MACs), 27–28, 31
  - Myeloproliferative neoplasms, 38–39
  - Myocardial infarction, 128, 284–285, 555–556
- N**
- Negative feedback loop, 17, 21–22, 283, 286–288, 404
  - Neuregulin-1 (NRG1), 29, 36
  - Neurodegenerative disease, blood–brain barrier in, 404–405
  - Neuroinflammation
    - BBB, effect on, 442
    - and S1P signaling, 265–266
  - Neurological disease, and lymphatic function, 387–388
  - Neuronal PAS domain protein 4 (NPAS4), 4
  - Neurovascular unit, 395–396
  - NF- $\kappa$ B pathway, 497
  - Nitric oxide (NO), 186–189, 370–371, 381–383
  - NORRIN/Fzd4 signaling, and blood–brain barrier, 401–402
  - Notch signaling
    - angiocrine functions, 248–250
    - during angiogenesis, 331–334
    - arterial-venous specification, 17–19
    - blood vessel patterning, 54–56, 66–67
    - button junctions, 219–220
    - counteraction of VEGF by, 187–188, 333
    - between endothelial and mural cells, 336–337
    - endothelial cell fate determination, 13–23, 332–333
    - in endothelial cells, 244–246
    - in endothelial cells during development, 330–331
    - hemogenic endothelial cell specification (HECS), 7
    - lymphatic specification, 20–21
    - lymphatic valve cell fate, 22–23
    - lymphatic vascular cell fate determination, 19–23
    - as master regulator, 246–248
    - in mature endothelial cells, 334
    - mechanosensing, 56
    - in mural cells, 334–336
    - in organ-specific vascular beds, 248–250
    - overview, 242–244, 327–330
    - sprouting lymphangiogenesis, 21–22
    - tip cell/stalk cell determination and shuffling, 14–16
    - vascular communication, 327–338
    - in the vasculature, 241–251
    - vessel maintenance and diseases, 249–251
    - Wnt signaling cross talk, 420–421
  - NSAIDs, 153–154
- O**
- Obesity
    - and cardiovascular disease, 551–553
    - lymphatic dysfunction linked to, 232–233, 552–553
    - lymphedema, 565–570
  - Obesity-induced lymphedema (OIL), 565–570
  - Organ-on-a-chip systems, 172–174
  - Organ vascularization
    - angiogenesis, 99
    - arteriovenous malformations, 108–115
    - blood vessel maturation, 100
    - endothelial heterogeneity and plasticity, 100–102
    - heart, 103–104
    - hemodynamic influence on, 99–100



## Index

- Organ vascularization (*Continued*)  
interorgan, 105–108  
kidney, 102–103  
lung, 104–105  
morphogenesis, 97–102  
overview, 102  
pancreas, 104  
vasculogenesis, 98–99  
Oxidative stress, 576, 578
- P**
- p27, 7  
Pancreas vascularization, 104  
Parkes Weber syndrome (PWS), 313  
Parkinson's disease, 387, 404–405  
Pericytes  
brain, 397  
endothelial cells interactions in cerebral cavernous malformations, 345–355  
growth factors controlling, 90–91  
recruitment and basement membrane assembly, 79, 81–83  
recruitment during sprouting angiogenesis, 16  
recruitment in blood vessel maturation, 98–100  
Periventricular vessel plexus, 57–59  
Permeability  
definitions of, 229–230  
lymphatic vascular, 227–236  
measurement methods, 230  
Platelet factor 4 (PF4), 136  
Platelet microparticles, 137  
Platelets  
lymphangiogenesis, 133–143  
in pathophysiological angiogenesis, 140–142  
in physiological angiogenesis, 137–140  
in separation of blood and lymphatic systems, 137–139  
storage and release of angiogenic regulators, 134–137  
vessel stabilization during neoangiogenesis, 138–139  
wound healing and tissue regeneration, 139–140  
Podoplanin, 138–139, 360–361  
Portal veins, 107–108  
Positive feedback loop, 4, 283, 285, 288–289, 350, 353  
Proliferative diabetic retinopathy (PDR), 141–142  
Prostaglandins. *See also* Prostanoids  
angiogenesis and lymphangiogenesis, 149–156, 158–161  
roles of, 151  
Prostanoids  
angiogenesis regulation, 151–155  
biosynthesis, 150–151  
lymphangiogenesis, regulation of tumor-associated, 159–160  
lymphangiogenesis regulation in inflammation, 155–158  
lymphangiogenesis regulation in lymphedema, 158–159  
lymphatic metastasis, regulation of, 159–160  
receptors, 151  
as therapeutic targets, 161–162  
tumor angiogenesis, 153–155  
*Prox1*, 19–23, 360–361, 380, 553  
Pulmonary arterial hypertension (PAH), 39–40  
Pulmonary fibrosis, 40, 196, 285, 288–291  
Pulsatile flow, 113–114
- R**
- Receptor tyrosine kinase signaling, 318–319  
Resolvins, 495, 498–508  
Retina, microvascular endothelium of, 270–271  
Retinoic acid signaling, 6–7  
Retinopathy, 141–142, 423–424, 503–504, 508  
Retinopathy of prematurity (ROP), 142  
Reverse cholesterol transport, 554  
Rheumatoid arthritis, 386, 502  
RhoA-Rho kinase (ROCK) pathway, 368–369  
Runx1, 7–9
- S**
- SARS-CoV-2, 142, 519–520, 522, 524–527. *See also* COVID-19  
Scarring, 139, 284–286  
Senescence, cellular, 579  
Sepsis, and S1P signaling, 265  
Shear stress  
endothelial-dependent responses, 370  
homeostatic regulation of, 287  
lymphatic vascular development, 319–320  
and miRNA deregulation, 290–292  
Notch activation, 246, 249  
Signaling in the endothelium, 259–275. *See also specific signaling pathways*  
Skin  
inflammation and lymphatic dysfunction, 386  
vascular patterning, 59–61  
Smooth muscle cells (SMCs), gap junctions in, 123  
Sonic hedgehog (SHH), 3  
Specialized pro-resolving mediators (SPMs), 495, 499–508  
Sphingosine-1-phosphate (S1P)  
blood vessels, 263–264  
chaperones, 260–261  
metabolism, 260  
overview, 259–260  
Sphingosine-1-phosphate receptors (S1PR)  
overview, 261  
regulation of gene expression, 267–274



- S1PR1, 267–272
- S1PR2, 272–273
- S1PR3, 273–274
- S1PR5, 274
- Sphingosine-1-phosphate (S1P) signaling
  - button junctions, 220
  - embryonic development, 263–264
  - leukocyte migration, 479–480
  - postnatal vascular functions, 264–267
- Sprouting angiogenesis
  - blood vessel patterning, 51–55, 57–62, 67
  - CNS vascular patterning, 57–59
  - coronary vascular patterning, 61–62
  - lymphatic, 21–22, 217
  - Notch signaling, 14–16, 333
  - overview, 98–99, 298–299
  - platelets, role of, 139
  - skin vascular patterning, 60
  - tip cell/stalk cell determination and shuffling, 14–16
- Stiffness, 283–292
- Stroke, 403–404
- T**
- T cell–endothelial cell interactions
  - in cancer, 464–465
  - overview, 459
  - step by step, 460–464
  - T-cell adhesion on vascular ECs, 462–463
  - T-cell locomotion/apical migration on vascular ECs, 463
  - T-cell rolling on vascular ECs, 461–462
  - T-cell transendothelial migration across vascular ECs, 463–464
- Tight junctions
  - blood–brain barrier, 395–398, 404, 424, 426, 442, 444–445
  - lymphatic endothelial cells, 211, 213
- Tip cell/stalk cell determination and shuffling, 14–16, 333
- Tissue architecture, reversible and nonreversible changes in, 286
- Tissue growth, role of angiogenesis in, 189–190
- Tissue regeneration
  - role of platelets in, 139–140
  - stimulation by pro-resolving mediators, 504–505
- Tissue stiffness, 283–292
- Transendothelial electrical resistance (TEER), 444–446
- Transendothelial migration (TEM), of T cells, 459–465
- Transforming growth factor  $\beta$  (TGF- $\beta$ ), 57, 187–189
- Transmural pressure, response to, 368, 370
- Traumatic brain injury, 403
- Triglyceride-rich lipoprotein (TRL), 536–539
- TSP-1/TSP-2, in platelets, 136
- Tubulogenesis, endothelial cell, 77–79, 89–90, 98
- Tumor angiogenesis
  - brain, 402
  - connexins role in, 126–128
  - exosomes, role of, 191–194
  - hypoxia stimulation of, 497–498
  - overview, 191
  - platelets, role of, 140–141
  - prostanoid effects on, 153–155
- Tumor-associated lymphangiogenesis, prostanoid regulation of, 159–160
- Tumor vasculature
  - angiogenesis in diseases, 191–194
  - S1P signaling, 266
- V**
- Vascular aging
  - cardiovascular disease, 573–574
  - cellular senescence, 579
  - and circulating factors, 580
  - ECM remodeling, perivascular fibrosis, and glycocalyx damage, 579–580
  - modeling, 581–586
  - organ-specific, 580–581
  - overview, 573–576
  - vascular microenvironment during, 576–580
- Vascular development, Wnt/PCP signaling in, 419
- Vascular endothelial cadherin (VE-cadherin)
  - in lymphatics, 211–220, 228–229, 231–235, 360–361
  - lymphatic vessel permeability, 231, 233, 235
  - Notch signaling, 245, 334
  - shear stress sensing, 56, 319
  - S1PR1 signaling, 264, 269–270
  - T-cell transendothelial migration, 463
- Vascular endothelial growth factor (VEGF)
  - angiogenesis and microvascular permeability regulation, 186–188
  - and blood–brain barrier (BBB), 398–400
  - blood vessel patterning, 52, 54–55, 57–59, 61, 64
  - brain tumor angiogenesis, 402
  - button junctions, effects on, 219
  - and cardiovascular diseases, 550–551, 553–556, 558
  - counteraction by Notch, 187–188
  - endocytosis of receptors, 300–304
  - endothelial cell differentiation, 5
  - as lymphatic marker, 360
  - lymphatic permeability disruption, 232–233
  - lymphatic sprouting, 21–22
  - lymphatic tissue and organ regeneration, 175–177, 179
  - lymphatic vascular development, 318
  - Notch signaling effects on, 245–247, 333
  - in platelets, 135–137
  - prostanoids, induction by, 150, 152, 154–161
  - receptors and ligands, 299–300
  - in retinopathies, 141–142
  - role in lipid metabolism, 541

## Index

- Vascular endothelial growth factor (VEGF) (*Continued*)  
  sprouting angiogenesis, 14–16  
  tumor angiogenesis, 192–193  
  Wnt signaling cross talk, 420
- Vascularization, ECM regulation of, 75–91
- Vascular morphogenesis, ECM regulation of, 75–91
- Vascular patterning. *See* Blood vessel patterning
- Vascular ring anomalies, 106–107
- Vascular smooth muscle cells (VSMCs)  
  coronary vascular patterning, 63  
  Notch signaling, 327–330, 334–337  
  recruitment during sprouting angiogenesis, 16  
  skin vascular patterning, 59–61
- Vasculogenesis, 98–99
- Vasculogenic mimicry, 141
- VEGF. *See* Vascular endothelial growth factor (VEGF)
- Venous regression, 107–108
- Vesicular transport, 231
- von Willebrand disease (vWD), 38
- W**
- Wnt/b-catenin signaling pathway, 57–59, 416–418, 420–426
- Wnt/Ca<sup>2+</sup> signaling pathway, 416–418
- Wnt/frizzled signaling pathway, 415–432
- Wnt/PCP signaling pathway, 416–419, 432
- Wnt signaling  
  blood–brain barrier vasculature, 424–426, 432  
  canonical pathway, 416–418  
  cross talk with other angiogenic pathways, 420–421  
  eye vasculature development, 421–422  
  overview, 415–416  
  retinal vascular diseases, 423–424  
  therapies for vascular diseases, 427–432
- Wound healing  
  prostanoid effect on, 151–152  
  role of angiogenesis in, 190–191  
  role of platelets in, 139–140  
  stimulation by pro-resolving mediators, 504–505
- Y**
- YAP/TAZ signaling, 220
- Z**
- Zipper junctions  
  button junctions compared, 205, 553  
  button to zipper conversion, 219–220, 234, 553  
  chylomicron uptake prevented by, 594  
  in collecting lymphatic vessels, 174, 215, 229, 310–311, 361, 380, 470–471  
  diagram, 213, 229  
  leakage prevention, 229, 310–311  
  role of, 361  
  zipper to button conversion, 229, 317